NADAC acquisition cost data for ESTRADIOL 2 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00555088702 | $0.1190 | 2022-12-21 | Rx |
| 00555088704 | $0.1190 | 2022-12-21 | Rx |
| 24658070401 | $0.1190 | 2022-12-21 | Rx |
| 24658070405 | $0.1190 | 2022-12-21 | Rx |
| 42806008901 | $0.1190 | 2022-12-21 | Rx |
| 42806008905 | $0.1190 | 2022-12-21 | Rx |
| 51862033401 | $0.1190 | 2022-12-21 | Rx |
| 51862033405 | $0.1190 | 2022-12-21 | Rx |
| 00555088702 | $0.1190 | 2022-12-21 | Rx |
| 00555088704 | $0.1190 | 2022-12-21 | Rx |
Generic: Estradiol | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $17.4M | 172,348 | 44,200 | $14.24 |
| 2020 | $20.2M | 180,971 | 42,247 | $14.72 |
| 2021 | $19.0M | 174,980 | 41,899 | $13.92 |
| 2022 | $19.4M | 176,908 | 44,789 | $14.03 |
| 2023 | $19.3M | 184,088 | 47,206 | $13.31 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $2.6M | 22,812 | 6,955 |
| Florida | $1.4M | 13,493 | 3,536 |
| Texas | $1.3M | 13,011 | 3,425 |
| New York | $794.9K | 7,633 | 1,905 |
| North Carolina | $756.8K | 7,776 | 1,910 |
| Michigan | $684.9K | 5,611 | 1,520 |
| Ohio | $665.4K | 6,470 | 1,657 |
| Pennsylvania | $654.8K | 6,301 | 1,506 |
| Washington | $566.5K | 5,115 | 1,379 |
| Colorado | $560.9K | 4,623 | 1,429 |
| Georgia | $558.5K | 5,883 | 1,479 |
| Oregon | $485.9K | 4,056 | 1,155 |
| Illinois | $449.5K | 4,132 | 1,088 |
| Massachusetts | $446.7K | 4,354 | 1,085 |
| Arizona | $442.7K | 4,024 | 1,113 |
| Tennessee | $417.6K | 4,180 | 1,055 |
| Minnesota | $402.7K | 2,970 | 842 |
| Indiana | $396.1K | 4,080 | 1,006 |
| Missouri | $364.1K | 3,644 | 869 |
| Virginia | $363.4K | 3,705 | 1,018 |
| Alabama | $347.8K | 3,308 | 771 |
| Kentucky | $342.2K | 3,851 | 890 |
| Louisiana | $333.8K | 4,101 | 877 |
| Oklahoma | $324.7K | 3,309 | 802 |
| South Carolina | $321.2K | 3,350 | 861 |
| Wisconsin | $300.1K | 2,538 | 655 |
| New Jersey | $254.1K | 2,298 | 590 |
| Maryland | $242.9K | 2,119 | 631 |
| Connecticut | $221.0K | 2,099 | 546 |
| Utah | $211.8K | 1,915 | 498 |
| Arkansas | $180.4K | 2,222 | 449 |
| Kansas | $172.3K | 1,881 | 444 |
| Nevada | $172.2K | 1,584 | 431 |
| Idaho | $148.5K | 1,421 | 358 |
| Mississippi | $147.7K | 1,877 | 406 |
| Iowa | $134.3K | 1,378 | 338 |
| New Mexico | $123.1K | 1,228 | 314 |
| West Virginia | $101.1K | 970 | 248 |
| Maine | $99.9K | 1,011 | 266 |
| Puerto Rico | $91.9K | 1,158 | 226 |
| Nebraska | $91.6K | 987 | 224 |
| New Hampshire | $86.3K | 857 | 232 |
| Rhode Island | $73.7K | 755 | 166 |
| Hawaii | $72.0K | 626 | 206 |
| Montana | $71.1K | 717 | 183 |
| Delaware | $50.2K | 385 | 115 |
| North Dakota | $46.3K | 434 | 110 |
| South Dakota | $45.8K | 461 | 110 |
| Wyoming | $45.3K | 424 | 110 |
| District of Columbia | $39.1K | 343 | 103 |
| Alaska | $34.1K | 302 | 84 |
| Vermont | $26.5K | 205 | 65 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.